{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:43:13Z","timestamp":1768290193522,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1038\/aps.2010.217","type":"journal-article","created":{"date-parts":[[2011,3,4]],"date-time":"2011-03-04T13:12:26Z","timestamp":1299244346000},"page":"408-414","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas"],"prefix":"10.1038","volume":"32","author":[{"given":"Yun","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neng-ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00fc-hong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-qin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,4]]},"reference":[{"key":"BFaps2010217_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM . Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467\u201375.","journal-title":"Ann Oncol"},{"key":"BFaps2010217_CR2","first-page":"4124","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124\u201330.","journal-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol"},{"key":"BFaps2010217_CR3","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","volume":"20","author":"M Nickelsen","year":"2009","unstructured":"Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2009; 20: 1977\u201384.","journal-title":"Ann Oncol"},{"key":"BFaps2010217_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 106\u201313.","journal-title":"J Clin Oncol"},{"key":"BFaps2010217_CR5","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/cncr.20531","volume":"101","author":"F Morabito","year":"2004","unstructured":"Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linfomi. Cancer 2004; 101: 1601\u20138.","journal-title":"Cancer"},{"key":"BFaps2010217_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T R\u00fcdiger","year":"2002","unstructured":"R\u00fcdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140\u20139.","journal-title":"Ann Oncol"},{"key":"BFaps2010217_CR7","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolinged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987\u201392.","journal-title":"Cancer Res"},{"key":"BFaps2010217_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz SR . Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42: 419\u201336.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps2010217_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/archderm.144.6.727","volume":"144","author":"G Quereux","year":"2008","unstructured":"Quereux G, Marques S, Nguyen JM, Bedane C, D'incan M, Dereure O, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or S\u00e9zary syndrome. Arch Dermatol 2008; 144: 727\u201333.","journal-title":"Arch Dermatol"},{"key":"BFaps2010217_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3324\/haematol.10879","volume":"92","author":"S Pulini","year":"2007","unstructured":"Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Tassetti A, et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica 2007; 92: 686\u20139.","journal-title":"Haematologica"},{"key":"BFaps2010217_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/10428190400013688","volume":"46","author":"G Visani","year":"2005","unstructured":"Visani G, Guiducci B, D'Adamo F, Mele A, Nicolini G, Leopardi G, et al. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 477\u20139.","journal-title":"Leuk Lymphoma"},{"key":"BFaps2010217_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0305-7372(02)80003-2","volume":"28","author":"J Crawford","year":"2002","unstructured":"Crawford J . Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev 2002; 28: 7\u201311.","journal-title":"Cancer Treat Rev"},{"key":"BFaps2010217_CR13","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/1097-0142(20010501)91:9<1826::AID-CNCR1203>3.0.CO;2-J","volume":"91","author":"RL Hong","year":"2001","unstructured":"Hong RL, Tseng YL . Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors. Cancer 2001; 91: 1826\u201333.","journal-title":"Cancer"},{"key":"BFaps2010217_CR14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00280-003-0583-2","volume":"51","author":"RL Hong","year":"2003","unstructured":"Hong RL, Tseng YL . A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003; 51: 433\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFaps2010217_CR15","first-page":"702","volume":"34","author":"ZH Pan","year":"2007","unstructured":"Pan ZH, Huang HQ, Cai QQ, Bo Q, Wang BF, Liao H . Clinical analysis of prognosis for 96 patients with peripheral T-cell lymphoma. Chin J Clin Oncol 2007; 34: 702\u20135.","journal-title":"Chin J Clin Oncol"},{"key":"BFaps2010217_CR16","doi-asserted-by":"crossref","unstructured":"Savage KJ . Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008: 280\u20138.","DOI":"10.1182\/asheducation-2008.1.280"},{"key":"BFaps2010217_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00280-003-0703-z","volume":"53","author":"SN Giri","year":"2004","unstructured":"Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC, Margolin SB . Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol 2004; 53: 141\u201350.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFaps2010217_CR18","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Blood 2010; 116: 3418\u201325.","journal-title":"Blood"},{"key":"BFaps2010217_CR19","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316\u201323.","journal-title":"Blood"},{"key":"BFaps2010217_CR20","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124\u201330.","journal-title":"J Clin Oncol"},{"key":"BFaps2010217_CR21","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/1097-0142(19941001)74:7+<2101::AID-CNCR2820741718>3.0.CO;2-M","volume":"74","author":"RJ Havlik","year":"1994","unstructured":"Havlik RJ, Yancik R, Long S, Ries L, Edwards B . The National Institute on Aging and the National Cancer Institute SEER collaborative study on co-morbidity and early diagnosis of cancer in the elderly. Cancer 1994; 74: 2101\u20136.","journal-title":"Cancer"},{"key":"BFaps2010217_CR22","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/archinternmed.2010.233","volume":"170","author":"HJ van der Pal","year":"2010","unstructured":"van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010; 170: 1247\u201355.","journal-title":"Arch Intern Med"},{"key":"BFaps2010217_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1254\/jphs.FPJ04001X","volume":"95","author":"WL Lu","year":"2004","unstructured":"Lu WL, Qi XR, Zhang Q, Li RY, Wang GL, Zhang RJ, et al. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J Pharmacol Sci 2004; 95: 381\u20139.","journal-title":"J Pharmacol Sci"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2010217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2010217","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2010217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:23:48Z","timestamp":1684412628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2010217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["BFaps2010217"],"URL":"https:\/\/doi.org\/10.1038\/aps.2010.217","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}